Publications by authors named "D Biery"
Article Synopsis
- Diabetes mellitus (DM) and elevated lipoprotein(a) [Lp(a)] are both significant predictors of coronary artery disease (CAD) outcomes, but their combined effects are not well understood.
- A study analyzing data from over 6,200 patients found that those with either condition had higher rates of cardiovascular death or myocardial infarction (MI), especially those with elevated Lp(a).
- Elevated Lp(a) was shown to be an independent risk factor for CAD outcomes, increasing risk for patients with or without DM.
Background: Lipoprotein (a) [Lp(a)] is a robust predictor of coronary heart disease outcomes, with targeted therapies currently under investigation. We aimed to evaluate the association of high Lp(a) with standard modifiable risk factors (SMuRFs) for incident first acute myocardial infarction (AMI).
Methods And Results: This retrospective study used the Mass General Brigham Lp(a) Registry, which included patients aged ≥18 years with an Lp(a) measurement between 2000 and 2019.
The strong association between lipoprotein (a) [Lp(a)] and atherosclerotic cardiovascular disease has led to considerations of Lp(a) being a potential target for mitigating residual cardiovascular risk. While approximately 20 % of the population has an Lp(a) level greater than 50 mg/dL, there are no currently available pharmacological lipid-lowering therapies that have demonstrated substantial reduction in Lp(a). Novel therapies to lower Lp(a) include antisense oligonucleotides and small-interfering ribonucleic acid molecules and have shown promising results in phase 2 trials.
View Article and Find Full Text PDF